Hemostemix Inc. Stock

HEM

CA4236943060

Biotechnology & Medical Research

Delayed Toronto S.E. 12:11:57 2026-09-11 EDT			5-day change	1st Jan Change
0.0700 ^CAD	-6.67%		-6.67%	-22.22%

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI

News in other languages : Hemostemix Inc.

25-02-10	Hemostemix : Casino auf gold
25-01-15	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
21-04-22	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
21-04-09	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors : Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	2020-02-09
Christina Wu DFI	Director of Finance/CFO	-	2020-03-04
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	2021-10-13

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	2019-11-25
Ronnie Hershmann BRD	Director/Board Member	67	2020-02-08
Loran Swanberg BRD	Director/Board Member	-	2020-04-07

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-11	$0.0700	-6.67%	37,900
26-09-10	$0.0750	0.00%	15,911
26-09-09	$0.0750	0.00%	2,000
26-09-08	$0.0750	0.00%	1,653
26-09-04	$0.0750	0.00%	2,777

Delayed Quote Toronto S.E.

More quotes

Market Cap	15.86M 11.43M 9.85M 9.33M 8.45M 1.09B 15.94M 111M 42.59M 556M 42.93M 41.99M 1.76B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	18.72M 13.49M 11.63M 11.01M 9.98M 1.29B 18.81M 131M 50.28M 656M 50.68M 49.56M 2.07B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	83.37%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Toronto S.E.	HEM	Delayed
OTC Markets	HMTXF	Delayed
Deutsche Boerse AG	2VF0	Delayed
Börse Stuttgart	2VF0	Delayed
Tradegate	2VF0	Real-time

09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI
07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-08	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-16	Hemostemix Inc. amended terms of the transaction	CI
05-29	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-25	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-20	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
04-30	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-30	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-18	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI
01-16	Hemostemix Receives FDA Support for Its Basket Protocol Approach	MT

08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA	NE
08-12	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU
08-12	Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial	NE
07-28	Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results	NE
07-22	Hemostemix : grants 6,280,000 options	PU

1 day	-6.67%
1 week	-6.67%
Current month	-6.67%
3 months	+27.27%
6 months	-17.65%
Current year	-22.22%

Hemostemix Inc. Stock

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation : Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news : Hemostemix Inc.

Press Releases : Hemostemix Inc.

News in other languages : Hemostemix Inc.

Quotes and Performance

Price Extremes

Managers and Directors : Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

1 week	0.07	0.08
1 month	0.06	0.08
Current year	0.04	0.11
1 year	0.04	0.12
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/30/26	Peter Lacey	Option	Chairman	525,000	0.2654%
7/22/26	Loran Swanberg	Option	Director	385,000	0.1946%
7/22/26	Thomas Smeenk	Option	Founder	1,730,000	0.8746%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	-6.67%	-6.67%	-41.67%	-44.00%	11.48M
WUXI APPTEC CO., LTD.	-2.11%	-3.44%	+41.04%	+98.48%	68.24B
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	62.23B
INSMED INCORPORATED	+0.00%	+0.58%	-12.87%	+379.32%	27.8B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-7.30%	+25.00%	+12.31%	24.86B
BIONTECH SE	+0.64%	-6.13%	-6.62%	-17.42%	24.22B
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	19.36B
PHARMAESSENTIA CORPORATION	-3.03%	-5.19%	+192.88%	+340.13%	17.28B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-6.36%	-7.05%	+516.16%	14.46B
EXELIXIS, INC.	-2.15%	-4.34%	+44.48%	+156.71%	14.23B
Average	-1.61%	-3.56%	+28.04%	+149.60%	27.27B
Weighted average by Cap.	-0.99%	-3.80%	+32.81%	+135.43%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.89M -1.62M -1.54M -1.39M -180M -2.63M -18.27M -7.03M -91.67M -7.08M -6.93M -290M	-4.71M -3.4M -2.93M -2.77M -2.51M -325M -4.74M -32.92M -12.66M -165M -12.76M -12.48M -522M
Net Debt	4.23M 3.05M 2.63M 2.49M 2.26M 291M 4.25M 29.55M 11.36M 148M 11.45M 11.2M 468M	2.86M 2.06M 1.78M 1.68M 1.52M 197M 2.88M 19.98M 7.68M 100M 7.74M 7.57M 317M